Protocols for treatment of major depressive disorder (MDD)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 21, 2017
Grant Date -
Dec 17, 2015
app pub date -
Jun 15, 2015
filing date -
Jun 16, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Although it is known that certain benzylpiperazine-aminopyridines or open chain forms thereof are effective in stimulating neural growth in in vitro tests, it has now been surprisingly found that administering these compounds in a dosage range of 10 mg/day-130 mg/day over 25-35 days is effective in treating Major Depressive Disorder (MDD) such that statistically significant results can be obtained with samples of only six subjects.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully